The concordance of RNA-sequencing (RNA-seq) with microarrays for genome-wide analysis of differential gene expression has not been rigorously assessed using a range of chemical treatment conditions.

Genomatix Software GmbH today announced that it has achieved GeneChip-compatible TM status for several products with the Affymetrix Inc. (Nasdaq: AFFX) GeneChip® microarray platform and that it has ...

Offerings Now Encompass Multiplex and Parallel Analysis of Cells, Proteins, and Genes Affymetrix, best known for its pioneering work in commercializing microarrays for gene expression research since ...

Affymetrix Showcases Third-Party Microarray Analysis Software Like it or not, biologists have to deal increasingly in informatics as their experiments generate ever larger and more complex data sets.

Affymetrix Inc. has announced the publication of the MicroArray Quality Control (MAQC) study, a collaborative effort led by the FDA that included 137 scientists from private and public sector ...

Unique and optimized solution provides highly sensitive and reproducible RNA amplification and labeling from archived FFPE samples for biomarker discovery and validation on industry-leading ...

Collaboration to expand research and molecular breeding tools for enhancing plant, crop, and livestock production outcomes SANTA CLARA, Calif.--(BUSINESS WIRE)-- Affymetrix, Inc. (NASDAQ:AFFX), ...

Microarray technology has come of age as a powerful approach to revealing the genome and its dynamic expression through the application of gene-hybridization or gene-expression microarrays. While the ...

Mindy Lee-Olsen, 408-731-5523 (Media)Vice President, Marketing ServicesorDoug Farrell, 408-731-5285 (Investors)Vice President, Investor Relations (NASDAQ:AFFX) announced today the availability of ...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Affymetrix Inc. (Nasdaq:AFFX) announced today that it has entered into a definitive agreement to acquire Panomics Inc., a privately held Fremont, Calif.-based ...

TEL AVIV (MarketWatch) -- Affymetrix Inc., the Santa Clara, Calif., developer of products based on genetic microarray technology, named Kevin M. King chief executive and a director, effective Jan. 1.